DAD9, a novel agonist concept that breaks the lethal partnership between α-synuclein and dopamine
Rosana Chehin, María del Milagro Teran, Valentina Budeguer Isa, Hernan Cruz, Rodrigo Hernan Tomas-Grau, Maria Laura Guayan, Agustin Pernicone, Verónica Manzano, Carla Beatriz Delprato, Diego De Mendoza, Oscar Varela, Diego Ploper · FENS Forum 2024
Aims: Recently, we introduced DAD9, a chemically-modified tetracycline (TC) conjugated to DA, creating a dopaminergic agonist with neuroprotective effects for Parkinson's Disease (PD). Our aim is to deepen the understanding of the molecular mechanisms underlying DAD9's neuroprotection.Methods: Characterization of α-Synuclein (α-Syn) oligomeric species was performed using ThT fluorescence, SDS-PAGE, DLS, and microscopy. Cell culture assays measured viability, cytotoxicity, and intracellular seeding in transgenic cell models. In vivo experiments were conducted in transgenic C. elegans.Results: T
ePoster · Neuroscience